NDA 019779 · Harrow Eye
Iopidine
Apraclonidine Hydrochloride · Ophthalmic
NovelLast checked: Nov 19, 2026Latest source record: Mar 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1987
Dec 31, 1987
Approved uses
2
Original approval plus efficacy supplements
Registered trials
8
4 Phase 3, 2 recruiting
FAERS reports
1
1 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 8, 2026.
INDICATIONS AND USAGE IOPIDINE 1% Ophthalmic Solution is indicated to control or prevent post-surgical elevations in IOP that occur in patients after argon laser trabeculoplasty, argon laser iridotomy or Nd:YAG posterior capsulotomy.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 15, 1989 Supplement 4 · Efficacy
- Dec 31, 1987 Original approval · Type 1 - New Molecular Entity
1 products under this application
- IOPIDINE · APRACLONIDINE HYDROCHLORIDE EQ 1% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Apraclonidine" as an intervention, any sponsor and status, largest first.
- An Investigation of FID 123320 for the Reduction of Ocular Redness in Pediatric and Adult PopulationsPivotal-lookingCompleted
Alcon ResearchIndustry
NCT06538662 · 284 participants · Start Oct 7, 2024 · Primary completion Jan 27, 2025
Drug: Apraclonidine Hydrochloride Ophthalmic Solution; Vehicle · For: Ocular Redness; Eye Irritation
Sites: Newport Beach, California; Colorado Springs, Colorado; Louisville, Kentucky · 8 sites in all
- Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in AdultsPivotal-lookingRecruiting
Alcon ResearchIndustry
NCT07531043 · 230 participants (planned) · Start Sep 30, 2026 · Primary completion Feb 2027
Drug: Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free; Vehicle · For: Ocular Hyperemia
Sites: Los Angeles, California; Newport Beach, California; Pittsburg, Kansas · 9 sites in all
- An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in AdultsPivotal-lookingRecruiting
Alcon ResearchIndustry
NCT07578363 · 178 participants (planned) · Start Sep 27, 2026 · Primary completion Nov 2026
Drug: Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free; Vehicle · For: Ocular Hyperemia
Sites: Northbrook, Illinois; Garner, North Carolina; Shelby, North Carolina · 5 sites in all
- A Double-Masked Comparison of FID 123320 Ophthalmic Solution to Vehicle for the Reduction of Ocular RednessPivotal-lookingCompleted
Alcon ResearchIndustry
NCT06444529 · 159 participants · Start Aug 21, 2024 · Primary completion Nov 14, 2024
Drug: Apraclonidine Hydrochloride Ophthalmic Solution; Vehicle · For: Ocular Redness
Sites: Glendale, California; Garner, North Carolina; Cranberry Township, Pennsylvania · 5 sites in all
- Iopidine to Decrease Intraocular Pressure Rise After InjectionsPivotal-lookingNot yet recruiting
Retina Consultants of DelmarvaAcademic, hospital or other
NCT07891910 · 120 participants (planned) · Start Oct 1, 2026 · Primary completion Dec 1, 2026
Drug: Apraclonidine 1.0% ophthalmic solution · For: Macular Degeneration; Diabetic Retinopathy; Retinal Vein Occlusion and 1 more
Sites: Easton, Maryland
- Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser TrabeculoplastyStatus unknown
Walter Reed Army Medical CenterFederal agency
NCT00567411 · 43 participants (planned) · Start Aug 2006
Drug: brimonidine 0.1%; Apraclonidine 0.5% · For: Glaucoma; Ocular Hypertension
Sites: Washington D.C., District of Columbia
- Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia GravisCompleted
American University of Beirut Medical CenterAcademic, hospital or other
NCT05045248 · 10 participants · Start Jun 1, 2020 · Primary completion Apr 15, 2021
Drug: Apraclonidine Hcl 0.5% Oph Soln · For: Myasthenia Gravis; Ocular Myasthenia Gravis
Sites: Beirut, Lebanon
University of Alabama at BirminghamAcademic, hospital or other
NCT05167760 · 0 participants · Start Dec 2025 · Primary completion Nov 2027
Drug: Apraclonidine · For: Synkinesis; Facial Nerve Palsy
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- retinal haemorrhage1
- retinopathy1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Iopidine (Apraclonidine HCl)
2024 spending
$37K
Beneficiaries
31
48 claims
Per beneficiary
$1,205
$26.80 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $37,350 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.
Li T, Lindsley K, Rouse B, et al. · Ophthalmology 2016 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Optogenetic Therapy for Restoring Aspects of Visual Function.
Sahel JA, Futterknecht S, Audo I, et al. · N Engl J Med 2026 · Clinical Trial, Phase I, Multicenter Study
- Apraclonidine and LASIK.
Aslanides IM, Tsiklis NS, Pallikaris IG, et al. · Ophthalmology 2005 · Comment, Letter
- Apraclonidine and my pupil.
Cambron M, Maertens H, Crevits L · Clin Auton Res 2011 · Clinical Trial
- Perioperative medications for preventing temporarily increased intraocular pressure after laser trabeculoplasty.
Zhang L, Weizer JS, Musch DC · Cochrane Database Syst Rev 2017 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Comparison of the postoperative intraocular pressure with Betagan, Betoptic, Timoptic, Iopidine, Diamox, Pilopine Gel, and Miostat.
Fry LL · J Cataract Refract Surg 1992 · Clinical Trial, Comparative Study
Sponsor: Harrow Eye
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.